Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ATLANTA, July 24, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2017, after the close of the financial markets on Wednesday, August 2, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, August 3, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Thursday, August 3, 2017 9:00AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' Second Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact CG CAPITAL Rich Cockrell 877.889.1972 [email protected]
